Introduction Eicosanoids are lipid mediators including thromboxanes (TXs), prostaglandins
(PGs) and leukotrienes (LTs) with a pathophysiological role in established atopic disease�…

Rationale: New approaches are needed to guide personalized treatment of asthma.
Objectives: To test if urinary eicosanoid metabolites can direct asthma phenotyping�…

Background Subcutaneous immunotherapy (SCIT) is an effective, safe, preventative
treatment for allergic asthma; however, potential biomarkers for monitoring SCIT have rarely�…

Background Aberrant generation of eicosanoids is associated with asthma, but the evidence
remains incomplete and its potential utility as biomarkers is unclear. Major eicosanoids in�…

Rationale Chronic endobronchial inflammation is a hallmark of pediatric asthma and
involves the arachidonic acid pathway. Its non‐volatile metabolites can be quantified in the�…

Atopic dermatitis (AD) is the most common and best characterized chronic eczematous skin
disorder. According to recent data, up to 10% of all children may be affected (1, 2). All�…

Prostanoids are unsaturated cyclic fatty acids, are synthesized primarily from arachidonic
acid, and, like the leukotrienes, belong to the growing family of eicosanoids. As tissue�…

Background Dysregulation of eicosanoids is associated with asthma and a composite of
oxylipins, including exhaled leukotriene B4 (LTB4), characterizes childhood asthma. While�…

Introduction: We hypothesised that asthma sub-phenotypes display distinct profiles of lipid
mediator metabolites in the urine. Methods: We quantified the urinary excretion of�…

Background Blood eosinophil count is a well‐established biomarker of atopic diseases in
older children and adults. However, its predictive role for atopic diseases in preschool�…